Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

被引：11

作者：

Borchmann, Peter ^{[1
]}

Haverkamp, Heinz ^{[1
]}

Lohri, Andreas ^{[2
]}

Kreissl, Stefanie ^{[1
]}

Greil, Richard ^{[3
]}

Markova, Jana ^{[4
]}

Feuring-Buske, Michaela ^{[5
]}

Meissner, Julia ^{[6
]}

Duehrsen, Ulrich ^{[7
]}

Engel, Nicole ^{[8
]}

Keller, Ulrich ^{[9
]}

Maschmeyer, Georg ^{[10
]}

Dietlein, Markus ^{[1
]}

Kobe, Carsten ^{[1
]}

Fuchs, Michael ^{[1
]}

Diehl, Volker ^{[1
]}

Engert, Andreas ^{[1
]}

机构：

[1] Univ Hosp Cologne, Cologne, Germany

[2] Med Univ Clin, Liestal, Switzerland

[3] Hosp Salzburg, Salzburg, Austria

[4] Charles Univ Prague, Fac Med 3, Prague, Czech Republic

[5] Univ Ulm, D-89069 Ulm, Germany

[6] Univ Heidelberg Hosp, Heidelberg, Germany

[7] Univ Duisburg Essen, Univ Hosp Essen, Essen, Germany

[8] Univ Munich, Munich, Germany

[9] Tech Univ Munich, D-80290 Munich, Germany

[10] Ernst von Bergmann Hosp, Potsdam, Germany

来源：

关键词：

D O I：

10.1182/blood.V124.21.500.500

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页数：3